{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T10:05:46Z","timestamp":1742983546812,"version":"3.40.3"},"publisher-location":"Singapore","reference-count":172,"publisher":"Springer Singapore","isbn-type":[{"type":"print","value":"9789811061400"},{"type":"electronic","value":"9789811061417"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-981-10-6141-7_4","type":"book-chapter","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T05:53:53Z","timestamp":1510898033000},"page":"89-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of Urinary Proteases in Bladder Cancer"],"prefix":"10.1007","author":[{"given":"Paulo","family":"Bastos","sequence":"first","affiliation":[]},{"given":"Sandra","family":"Magalh\u00e3es","sequence":"additional","affiliation":[]},{"given":"L\u00facio Lara","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Vitorino","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,11,18]]},"reference":[{"key":"4_CR1","unstructured":"Ferlay J, Soerjomataram I, Ervik M et al (2014) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012: IARC CancerBase No. 11. Int. Agency Res. Cancer"},{"key":"4_CR2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00345-011-0709-9","volume":"29","author":"H Fajkovic","year":"2011","unstructured":"Fajkovic H, Halpern JA, Cha EK et al (2011) Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 29:457\u2013463","journal-title":"World J Urol"},{"key":"4_CR3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1078-1439(03)00139-X","volume":"22","author":"R Madeb","year":"2004","unstructured":"Madeb R, Messing EM (2004) Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol Semin Orig Investig 22:86\u201392","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1289\/ehp.8349201","volume":"49","author":"GT Bryan","year":"1983","unstructured":"Bryan GT (1983) Pathogenesis of human urinary bladder cancer. Environ Health Perspect 49:201\u2013207","journal-title":"Environ Health Perspect"},{"key":"4_CR5","unstructured":"Lopez-Beltran A, Sauter G, Gasser T et al (2004) World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. Pathol Genet tumors Urin Syst Male Genit Organs"},{"key":"4_CR6","unstructured":"WHO (2011) Environmental and occupational cancers. Fact sheet N\u00b0350"},{"key":"4_CR7","unstructured":"Bethesda (2016) PDQ adult treatment editorial board. bladder cancer treatment (PDQ\u00ae): health professional version. Natl Cancer Inst"},{"key":"4_CR8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","volume":"32","author":"C Yeung","year":"2014","unstructured":"Yeung C, Dinh T, Lee J (2014) The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics 32:1093\u20131104","journal-title":"Pharmacoeconomics"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ucl.2015.01.005","volume":"42","author":"DC Johnson","year":"2015","unstructured":"Johnson DC, Greene PS, Nielsen ME (2015) Surgical advances in bladder cancer: at what cost? Urol Clin North Am 42:235\u2013252","journal-title":"Urol Clin North Am"},{"key":"4_CR10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOU.0000000000000078","volume":"24","author":"M Mossanen","year":"2014","unstructured":"Mossanen M, Gore JL (2014) The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol 24:487\u2013491","journal-title":"Curr Opin Urol"},{"key":"4_CR11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","volume":"66","author":"RS Svatek","year":"2014","unstructured":"Svatek RS, Hollenbeck BK, Holm\u00e4ng S et al (2014) The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 66:253\u2013262","journal-title":"Eur Urol"},{"key":"4_CR12","doi-asserted-by":"crossref","unstructured":"Rodrigues D, Jer\u00f3nimo C, Henrique R et al (2016) Biomarkers in bladder cancer: a metabolomic approach using in vitro and ex vivo model systems. Int J Cancer n\/a\u2013n\/a","DOI":"10.1002\/ijc.30016"},{"key":"4_CR13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2011.03.023","volume":"59","author":"A Stenzl","year":"2011","unstructured":"Stenzl A, Cowan NC, De Santis M et al (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59:1009\u20131018","journal-title":"Eur Urol"},{"key":"4_CR14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.urology.2003.10.038","volume":"63","author":"AM Kamat","year":"2004","unstructured":"Kamat AM, Lamm DL (2004) Antitumor activity of common antibiotics against superficial bladder cancer. Urology 63:457\u2013460","journal-title":"Urology"},{"key":"4_CR15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10552-007-9104-7","volume":"19","author":"AS Felix","year":"2008","unstructured":"Felix AS, Soliman AS, Khaled H et al (2008) The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control 19:421\u2013429","journal-title":"Cancer Causes Control"},{"key":"4_CR16","first-page":"3899","volume":"15","author":"CF Heyns","year":"2008","unstructured":"Heyns CF, van der Merwe A (2008) Bladder cancer in Africa. Can J Urol 15:3899\u20133908","journal-title":"Can J Urol"},{"key":"4_CR17","first-page":"8205836","volume":"2016","author":"M Nagata","year":"2016","unstructured":"Nagata M, Muto S, Horie S (2016) Molecular biomarkers in bladder cancer: novel potential indicators of prognosis and treatment outcomes. Dis Mark 2016:8205836","journal-title":"Dis Mark"},{"key":"4_CR18","doi-asserted-by":"crossref","unstructured":"Kaufman DS, Shipley WU, Feldman AS (18AD) Bladder cancer. Lancet 374:239\u2013249","DOI":"10.1016\/S0140-6736(09)60491-8"},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ctrv.2016.03.005","volume":"45","author":"F Massari","year":"2016","unstructured":"Massari F, Ciccarese C, Santoni M et al (2016) Metabolic phenotype of bladder cancer. Cancer Treat Rev 45:46\u201357","journal-title":"Cancer Treat Rev"},{"key":"4_CR20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.juro.2009.03.076","volume":"182","author":"C Lodillinsky","year":"2009","unstructured":"Lodillinsky C, Rodriguez V, Vauthay L et al (2009) Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer. J Urol 182:749\u2013755","journal-title":"J Urol"},{"key":"4_CR21","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0090-4295(00)01087-6","volume":"57","author":"S Gerhards","year":"2001","unstructured":"Gerhards S, Jung K, Koenig F et al (2001) Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 57:675\u2013679","journal-title":"Urology"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/1055-9965.EPI-14-0035","volume":"23","author":"CJ Rosser","year":"2014","unstructured":"Rosser CJ, Chang M, Dai Y et al (2014) Urinary protein biomarker panel for the detection of recurrent bladder cancer. Cancer Epidemiol Biomark Prev 23:1340\u20131345","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1586\/14737140.7.8.1105","volume":"7","author":"T Lam","year":"2007","unstructured":"Lam T, Nabi G (2007) Potential of urinary biomarkers in early bladder cancer diagnosis. Expert Rev Anticancer Ther 7:1105\u20131115","journal-title":"Expert Rev Anticancer Ther"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1158\/1078-0432.CCR-10-3121","volume":"17","author":"N Yang","year":"2011","unstructured":"Yang N, Feng S, Shedden K et al (2011) Urinary glycoprotein biomarker discovery for bladder cancer detection using LC\/MS-MS and label-free quantification. Clin Cancer Res 17:3349\u20133359","journal-title":"Clin Cancer Res"},{"key":"4_CR25","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1158\/1055-9965.EPI-12-0428","volume":"21","author":"V Urquidi","year":"2012","unstructured":"Urquidi V, Goodison S, Cai Y et al (2012) A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomark Prev 21:2149\u20132158","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"4_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.11648\/j.ajcem.20140201.11","volume":"2","author":"F Ye","year":"2014","unstructured":"Ye F, Wang L, Castillo-Martin M et al (2014) Biomarkers for bladder cancer management: present and future. Am J Clin Exp Urol 2:1\u201314","journal-title":"Am J Clin Exp Urol"},{"key":"4_CR27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/clinchem\/46.5.595","volume":"46","author":"M Burchardt","year":"2000","unstructured":"Burchardt M, Burchardt T, Shabsigh A et al (2000) Current concepts in biomarker technology for bladder cancers. Clin Chem 46:595\u2013605","journal-title":"Clin Chem"},{"key":"4_CR28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/10409239409083484","volume":"29","author":"SS Twining","year":"1994","unstructured":"Twining SS (1994) Regulation of proteolytic activity in tissues. Crit Rev Biochem Mol Biol 29:315\u2013383","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"4_CR29","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bbrc.2014.03.053","volume":"446","author":"C Li","year":"2014","unstructured":"Li C, Li H, Zhang T et al (2014) Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis. Biochem Biophys Res Commun 446:1047\u20131052","journal-title":"Biochem Biophys Res Commun"},{"key":"4_CR30","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1158\/1078-0432.CCR-08-1136","volume":"14","author":"R Roy","year":"2008","unstructured":"Roy R, Louis G, Loughlin KR et al (2008) Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 14:6610\u20136617","journal-title":"Clin Cancer Res"},{"key":"4_CR31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clgc.2012.06.003","volume":"11","author":"T Lei","year":"2013","unstructured":"Lei T, Zhao X, Jin S et al (2013) Discovery of potential bladder cancer biomarkers by comparative urine proteomics and analysis. Clin Genitourin Cancer 11:56\u201362","journal-title":"Clin Genitourin Cancer"},{"key":"4_CR32","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1021\/pr3008732","volume":"11","author":"CL Chen","year":"2012","unstructured":"Chen CL, Lai YF, Tang P et al (2012) Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res 11:5611\u20135629","journal-title":"J Proteome Res"},{"key":"4_CR33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/pmic.201000810","volume":"12","author":"M Lind\u00e9n","year":"2012","unstructured":"Lind\u00e9n M, Lind SB, Mayrhofer C et al (2012) Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics 12:135\u2013144","journal-title":"Proteomics"},{"key":"4_CR34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.juro.2009.08.109","volume":"183","author":"K-H Tsui","year":"2010","unstructured":"Tsui K-H, Tang P, Lin C-Y et al (2010) Bikunin loss in urine as useful marker for bladder carcinoma. J Urol 183:339\u2013344","journal-title":"J Urol"},{"key":"4_CR35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00345-009-0432-y","volume":"28","author":"LB Tan","year":"2010","unstructured":"Tan LB, Chen KT, Yuan YC et al (2010) Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis. World J Urol 28:117\u2013122","journal-title":"World J Urol"},{"key":"4_CR36","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/1078-0432.CCR-08-1143","volume":"15","author":"AS Feldman","year":"2009","unstructured":"Feldman AS, Banyard J, Wu C-L et al (2009) Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res 15:1024\u20131031","journal-title":"Clin Cancer Res"},{"key":"4_CR37","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1021\/pr700775x","volume":"7","author":"DM Smalley","year":"2008","unstructured":"Smalley DM, Sheman NE, Nelson K, Theodorescu D (2008) Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res 7:2088\u20132096","journal-title":"J Proteome Res"},{"key":"4_CR38","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1002\/pmic.200600066","volume":"6","author":"C-Y Lin","year":"2006","unstructured":"Lin C-Y, Tsui K-H, Yu C-C et al (2006) Searching cell-secreted proteomes for potential urinary bladder tumor markers. Proteomics 6:4381\u20134389","journal-title":"Proteomics"},{"key":"4_CR39","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.urology.2004.01.018","volume":"63","author":"A Staack","year":"2004","unstructured":"Staack A, Tolic D, Kristiansen G et al (2004) Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder. Urology 63:1089\u20131094","journal-title":"Urology"},{"issue":"2","key":"4_CR40","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.juro.2007.09.037","volume":"179","author":"Robert S. Svatek","year":"2008","unstructured":"Svatek RS, Karam J, Karakiewicz PI et al (2008) Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. J Urol 179:478\u2013484. (discussion 484)","journal-title":"The Journal of Urology"},{"key":"4_CR41","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1600-0854.2009.00929.x","volume":"10","author":"F Ulrich","year":"2009","unstructured":"Ulrich F, Heisenberg CP (2009) Trafficking and cell migration. Traffic 10:811\u2013818","journal-title":"Traffic"},{"key":"4_CR42","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.2741\/1915","volume":"11","author":"CJ Malemud","year":"2006","unstructured":"Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11:1696","journal-title":"Front Biosci"},{"key":"4_CR43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1742-4658.2010.07920.x","volume":"278","author":"E Hadler-Olsen","year":"2011","unstructured":"Hadler-Olsen E, Fadnes B, Sylte I et al (2011) Regulation of matrix metalloproteinase activity in health and disease. FEBS J 278:28\u201345","journal-title":"FEBS J"},{"key":"4_CR44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jprot.2013.04.024","volume":"85","author":"C-L Chen","year":"2013","unstructured":"Chen C-L, Lin T-S, Tsai C-H et al (2013) Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics. J Proteomics 85:28\u201343","journal-title":"J Proteomics"},{"key":"4_CR45","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1021\/ac060881d","volume":"78","author":"HJ Lee","year":"2006","unstructured":"Lee HJ, Nedelkov D, Corn RM (2006) Surface plasmon resonance imaging measurements of antibody arrays for the multiplexed detection of low molecular weight protein biomarkers. Anal Chem 78:6504\u20136510","journal-title":"Anal Chem"},{"key":"4_CR46","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00216-008-2448-3","volume":"393","author":"J Ladd","year":"2009","unstructured":"Ladd J, Taylor AD, Piliarik M et al (2009) Label-free detection of cancer biomarker candidates using surface plasmon resonance imaging. Anal Bioanal Chem 393:1157\u20131163","journal-title":"Anal Bioanal Chem"},{"key":"4_CR47","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3892\/ol.2014.2250","volume":"8","author":"E Gorodkiewicz","year":"2014","unstructured":"Gorodkiewicz E, Guszcz T, Roszkowska-Jakimiec W, Koz\u0142owski R (2014) Cathepsin D serum and urine concentration in superficial and invasive transitional bladder cancer as determined by surface plasmon resonance imaging. Oncol Lett 8:1323\u20131327","journal-title":"Oncol Lett"},{"key":"4_CR48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2490-13-25","volume":"13","author":"MA Mohammed","year":"2013","unstructured":"Mohammed MA, Seleim MF, Abdalla MS et al (2013) Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer. BMC Urol 13:25","journal-title":"BMC Urol"},{"key":"4_CR49","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0022-5347(01)61684-7","volume":"161","author":"E \u00d5zdemir","year":"1999","unstructured":"\u00d5zdemir E, Kakehi Y, Okuno H, Yoshida O (1999) Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J Urol 161:1359\u20131363","journal-title":"J Urol"},{"key":"4_CR50","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.eururo.2007.04.006","volume":"52","author":"S Eissa","year":"2007","unstructured":"Eissa S, Ali-Labib R, Swellam M et al (2007) Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol 52:1388\u20131397","journal-title":"Eur Urol"},{"key":"4_CR51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1006\/abio.2001.5479","volume":"301","author":"S Hattori","year":"2002","unstructured":"Hattori S, Fujisaki H, Kiriyama T et al (2002) Real-time zymography and reverse zymography: a method for detecting activities of matrix metalloproteinases and their inhibitors using FITC-labeled collagen and casein as substrates. Anal Biochem 301:27\u201334","journal-title":"Anal Biochem"},{"key":"4_CR52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nmeth.2371","volume":"10","author":"J Vandooren","year":"2013","unstructured":"Vandooren J, Geurts N, Martens E et al (2013) Zymography methods for visualizing hydrolytic enzymes. Nat Methods 10:211\u2013220","journal-title":"Nat Methods"},{"key":"4_CR53","first-page":"1395","volume":"58","author":"MA Moses","year":"1998","unstructured":"Moses MA, Wiederschain D, Loughlin KR et al (1998) Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58:1395\u20131399","journal-title":"Cancer Res"},{"issue":"7","key":"4_CR54","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/MPA.0000000000000573","volume":"45","author":"Bastian Sch\u00f6nemeier","year":"2016","unstructured":"Sch\u00f6nemeier B, Metzger J, Klein J, et al (2016) Urinary peptide analysis differentiates pancreatic cancer from chronic pancreatitis. Pancreas 45(7):1018\u20131026","journal-title":"Pancreas"},{"key":"4_CR55","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(06)70584-8","volume":"7","author":"D Theodorescu","year":"2006","unstructured":"Theodorescu D, Wittke S, Ross MM et al (2006) Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 7:230\u2013240","journal-title":"Lancet Oncol"},{"key":"4_CR56","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/pr800401m","volume":"8","author":"J Jantos-Siwy","year":"2009","unstructured":"Jantos-Siwy J, Schiffer E, Brand K et al (2009) Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 8:268\u2013281","journal-title":"J Proteome Res"},{"issue":"16","key":"4_CR57","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-15-2715","volume":"22","author":"Maria Frantzi","year":"2016","unstructured":"Frantzi M, Van Kessel KE, Zwarthoff EC et al (2016) Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study. Clin Cancer Res 22(16):4077\u20134086","journal-title":"Clinical Cancer Research"},{"key":"4_CR58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/pr0502525","volume":"5","author":"V Thongboonkerd","year":"2006","unstructured":"Thongboonkerd V, Chutipongtanate S, Kanlaya R (2006) Systematic evaluation of sample preparation methods for gel-based human urinary proteomics: quantity, quality, and variability. J Proteome Res 5:183\u2013191","journal-title":"J Proteome Res"},{"key":"4_CR59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbrc.2014.08.016","volume":"452","author":"M Sedic","year":"2014","unstructured":"Sedic M, Gethings LA, Vissers JPC et al (2014) Label-free mass spectrometric profiling of urinary proteins and metabolites from paediatric idiopathic nephrotic syndrome. Biochem Biophys Res Commun 452:21\u201326","journal-title":"Biochem Biophys Res Commun"},{"key":"4_CR60","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bbapap.2013.05.008","volume":"1844","author":"JW Froehlich","year":"2014","unstructured":"Froehlich JW, Vaezzadeh AR, Kirchner M et al (2014) An in-depth comparison of the male pediatric and adult urinary proteomes. Biochim Biophys Acta 1844:1044\u20131050","journal-title":"Biochim Biophys Acta"},{"key":"4_CR61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pcad.2012.04.009","volume":"55","author":"MAE Valente","year":"2012","unstructured":"Valente MAE, Damman K, Dunselman PHJM et al (2012) Urinary proteins in heart failure. Prog Cardiovasc Dis 55:44\u201355","journal-title":"Prog Cardiovasc Dis"},{"key":"4_CR62","unstructured":"Thongboonkerd V (2008) Urinary proteomics\u202f: towards biomarker discovery. Diagn Prognostics. 810\u2013815"},{"key":"4_CR63","doi-asserted-by":"crossref","unstructured":"Lokeshwar VB, Habuchi T, Grossman HB et al (2005) Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology:35\u201363","DOI":"10.1016\/j.urology.2005.08.064"},{"key":"4_CR64","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.urolonc.2005.11.023","volume":"24","author":"BR Konety","year":"2006","unstructured":"Konety BR (2006) Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 24:326\u2013337","journal-title":"Urol Oncol"},{"key":"4_CR65","doi-asserted-by":"crossref","unstructured":"Dancik GM (2015) An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancer. BMC Urol 15","DOI":"10.1186\/s12894-015-0056-z"},{"key":"4_CR66","doi-asserted-by":"crossref","first-page":"e38863","DOI":"10.1371\/journal.pone.0038863","volume":"7","author":"D Lindgren","year":"2012","unstructured":"Lindgren D, Sj\u00f6dahl G, Lauss M et al (2012) integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE 7:e38863","journal-title":"PLoS ONE"},{"key":"4_CR67","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1158\/0008-5472.CAN-09-4213","volume":"70","author":"D Lindgren","year":"2010","unstructured":"Lindgren D, Frigyesi A, Gudjonsson S et al (2010) Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 70:3463\u20133472","journal-title":"Cancer Res"},{"key":"4_CR68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-4598-9-3","volume":"9","author":"W-J Kim","year":"2010","unstructured":"Kim W-J, Kim E-J, Kim S-K et al (2010) Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 9:3","journal-title":"Mol Cancer"},{"key":"4_CR69","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-11-2271","volume":"18","author":"M Riester","year":"2012","unstructured":"Riester M, Taylor JM, Feifer A et al (2012) Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 18:1323\u20131333","journal-title":"Clin Cancer Res"},{"key":"4_CR70","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1158\/1078-0432.CCR-04-2409","volume":"11","author":"E Blaveri","year":"2005","unstructured":"Blaveri E, Simko JP, Korkola JE et al (2005) Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 11:4044\u20134055","journal-title":"Clin Cancer Res"},{"key":"4_CR71","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1158\/1078-0432.CCR-06-2940","volume":"13","author":"L Dyrskj\u00f8t","year":"2007","unstructured":"Dyrskj\u00f8t L, Zieger K, Real FX et al (2007) Gene expression signatures predict outcome in non\u2013muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 13:3545\u20133551","journal-title":"Clin Cancer Res"},{"key":"4_CR72","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/0008-5472.CAN-03-3620","volume":"64","author":"L Dyrskj\u00f8t","year":"2004","unstructured":"Dyrskj\u00f8t L, Kruh\u00f8ffer M, Thykjaer T et al (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64:4040\u20134048","journal-title":"Cancer Res"},{"key":"4_CR73","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1158\/0008-5472.CAN-11-3966","volume":"72","author":"SC Smith","year":"2012","unstructured":"Smith SC, Baras AS, Owens CR et al (2012) Transcriptional signatures of ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Res 72:3480\u20133491","journal-title":"Cancer Res"},{"key":"4_CR74","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2005.03.2375","volume":"24","author":"M Sanchez-Carbayo","year":"2006","unstructured":"Sanchez-Carbayo M, Socci ND, Lozano J et al (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24:778\u2013789","journal-title":"J Clin Oncol"},{"key":"4_CR75","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152\u2013165","journal-title":"Cancer Cell"},{"key":"4_CR76","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4161\/19336918.2014.970026","volume":"8","author":"L Atapattu","year":"2014","unstructured":"Atapattu L, Lackmann M, Janes PW (2014) The role of proteases in regulating eph\/ephrin signaling. Cell Adh Migr 8:294\u2013307","journal-title":"Cell Adh Migr"},{"key":"4_CR77","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/cmdc.201200057","volume":"7","author":"S Serim","year":"2012","unstructured":"Serim S, Haedke U, Verhelst SHL (2012) Activity-based probes for the study of proteases: recent advances and developments. ChemMedChem 7:1146\u20131159","journal-title":"ChemMedChem"},{"key":"4_CR78","doi-asserted-by":"crossref","first-page":"30433","DOI":"10.1074\/jbc.R800035200","volume":"283","author":"C L\u00f3pez-Ot\u00edn","year":"2008","unstructured":"L\u00f3pez-Ot\u00edn C, Bond JS (2008) Proteases: multifunctional enzymes in life and disease. J Biol Chem 283:30433\u201330437","journal-title":"J Biol Chem"},{"key":"4_CR79","doi-asserted-by":"crossref","first-page":"302","DOI":"10.7150\/ijbs.14996","volume":"12","author":"K Felix","year":"2016","unstructured":"Felix K, Gaida MM (2016) Neutrophil-derived proteases in the microenvironment of pancreatic cancer -active players in tumor progression. Int J Biol Sci 12:302\u2013313","journal-title":"Int J Biol Sci"},{"key":"4_CR80","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.3390\/biom5043260","volume":"5","author":"MZI Pranjol","year":"2015","unstructured":"Pranjol MZI, Gutowski N, Hannemann M, Whatmore J (2015) The potential role of the proteases cathepsin D and cathepsin L in the progression and metastasis of epithelial ovarian cancer. Biomolecules 5:3260\u20133279","journal-title":"Biomolecules"},{"key":"4_CR81","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrc4027","volume":"15","author":"OC Olson","year":"2015","unstructured":"Olson OC, Joyce JA (2015) Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer 15:712\u2013729","journal-title":"Nat Rev Cancer"},{"key":"4_CR82","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrd3053","volume":"9","author":"M Drag","year":"2010","unstructured":"Drag M, Salvesen GS (2010) Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 9:690\u2013701","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"4_CR83","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd2092","volume":"5","author":"Boris Turk","year":"2006","unstructured":"Turk B (2006) Targeting proteases\u202f: successes, failures and future prospects. Nat Rev Drug Discov 5(9):785\u2013799","journal-title":"Nature Reviews Drug Discovery"},{"key":"4_CR84","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.addr.2015.12.020","volume":"97","author":"J Vandooren","year":"2016","unstructured":"Vandooren J, Opdenakker G, Loadman PM, Edwards DR (2016) Proteases in cancer drug delivery. Adv Drug Deliv Rev 97:144\u2013155","journal-title":"Adv Drug Deliv Rev"},{"key":"4_CR85","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nrc2228","volume":"7","author":"C L\u00f3pez-Ot\u00edn","year":"2007","unstructured":"L\u00f3pez-Ot\u00edn C, Matrisian LM (2007) Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7:800\u2013808","journal-title":"Nat Rev Cancer"},{"key":"4_CR86","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/cc.6.1.3669","volume":"6","author":"V Gocheva","year":"2007","unstructured":"Gocheva V, Joyce JA (2007) Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6:60\u201364","journal-title":"Cell Cycle"},{"issue":"2","key":"4_CR87","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1074-7613(00)80020-5","volume":"10","author":"Guo-Ping Shi","year":"1999","unstructured":"Shi GP, Villadangos J a, Dranoff G et al (1999) Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 10:197\u2013206","journal-title":"Immunity"},{"key":"4_CR88","doi-asserted-by":"crossref","first-page":"6664","DOI":"10.1073\/pnas.1131604100","volume":"100","author":"J Bania","year":"2003","unstructured":"Bania J, Gatti E, Lelouard H et al (2003) Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs. Proc Natl Acad Sci U S A 100:6664\u20136669","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4_CR89","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1073\/pnas.092637699","volume":"99","author":"J Stypmann","year":"2002","unstructured":"Stypmann J, Gl\u00e4ser K, Roth W et al (2002) Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci U S A 99:6234\u20136239","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4_CR90","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1101\/gad.1407406","volume":"20","author":"V Gocheva","year":"2006","unstructured":"Gocheva V, Zeng W, Ke D et al (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20:543\u2013556","journal-title":"Genes Dev"},{"key":"4_CR91","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.prp.2008.04.010","volume":"204","author":"D Kuester","year":"2008","unstructured":"Kuester D, Lippert H, Roessner A, Krueger S (2008) The cathepsin family and their role in colorectal cancer. Pathol Res Pract 204:491\u2013500","journal-title":"Pathol Res Pract"},{"key":"4_CR92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cellimm.2008.10.001","volume":"255","author":"C Stoeckle","year":"2009","unstructured":"Stoeckle C, Sommandas V, Adamopoulou E et al (2009) Cathepsin G is differentially expressed in primary human antigen-presenting cells. Cell Immunol 255:41\u201345","journal-title":"Cell Immunol"},{"key":"4_CR93","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/38.8.2164060","volume":"38","author":"HA Kargi","year":"1990","unstructured":"Kargi HA, Campbell EJ, Kuhn C 3rd (1990) Elastase and cathepsin G of human monocytes: heterogeneity and subcellular localization to peroxidase-positive granules. J Histochem Cytochem 38:1179\u20131186","journal-title":"J Histochem Cytochem"},{"key":"4_CR94","doi-asserted-by":"crossref","first-page":"930","DOI":"10.2353\/ajpath.2007.060486","volume":"170","author":"N Shimoda","year":"2007","unstructured":"Shimoda N, Fukazawa N, Nonomura K, Fairchild RL (2007) Cathepsin g is required for sustained inflammation and tissue injury after reperfusion of ischemic kidneys. Am J Pathol 170:930\u2013940","journal-title":"Am J Pathol"},{"key":"4_CR95","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/416291a","volume":"416","author":"EP Reeves","year":"2002","unstructured":"Reeves EP, Lu H, Jacobs HL et al (2002) Killing activity of neutrophils is mediated through activation of proteases by K+flux. Nature 416:291\u2013297","journal-title":"Nature"},{"key":"4_CR96","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1074-7613(00)80173-9","volume":"12","author":"J Tkalcevic","year":"2000","unstructured":"Tkalcevic J, Novelli M, Phylactides M et al (2000) Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity 12:201\u2013210","journal-title":"Immunity"},{"key":"4_CR97","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1083\/jcb.131.3.775","volume":"131","author":"CA Owen","year":"1995","unstructured":"Owen CA, Campbell MA, Sannes PL et al (1995) Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol 131:775\u2013789","journal-title":"J Cell Biol"},{"key":"4_CR98","doi-asserted-by":"crossref","unstructured":"Brinkmann V, Reichard U, Goosmann C et al (2004) Neutrophil extracellular traps kill bacteria. Science (80) 303:1532\u20131535","DOI":"10.1126\/science.1092385"},{"key":"4_CR99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0167-4838(98)00085-5","volume":"1386","author":"J Polanowska","year":"1998","unstructured":"Polanowska J, Krokoszynska I, Czapinska H et al (1998) Specificity of human cathepsin G. Biochim Biophys Acta 1386:189\u2013198","journal-title":"Biochim Biophys Acta"},{"key":"4_CR100","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.4049\/jimmunol.1002292","volume":"185","author":"WW Raymond","year":"2010","unstructured":"Raymond WW, Trivedi NN, Makarova A et al (2010) How immune peptidases change specificity: cathepsin G gained tryptic function but lost efficiency during primate evolution. J Immunol 185:5360\u20135368","journal-title":"J Immunol"},{"key":"4_CR101","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1172\/JCI0213462","volume":"109","author":"AM Adkison","year":"2002","unstructured":"Adkison AM, Raptis SZ, Kelley DG, Pham CTN (2002) Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 109:363\u2013371","journal-title":"J Clin Invest"},{"key":"4_CR102","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1074\/jbc.275.10.6819","volume":"275","author":"GR Sambrano","year":"2000","unstructured":"Sambrano GR, Huang W, Faruqi T et al (2000) Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem 275:6819\u20136823","journal-title":"J Biol Chem"},{"key":"4_CR103","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4049\/jimmunol.147.3.921","volume":"147","author":"CM Maison","year":"1991","unstructured":"Maison CM, Villiers CL, Colomb MG (1991) Proteolysis of C3 on U937 cell plasma membranes. Purif Cathepsin G. J Immunol 147:921\u2013926","journal-title":"Purif Cathepsin G. J Immunol"},{"key":"4_CR104","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0268-9499(05)80019-0","volume":"8","author":"B Drag","year":"1994","unstructured":"Drag B, Petersen LC (1994) Activation of pro-urokinase by cathepsin G in the presence of glucosaminoglycans. Fibrinolysis 8:192\u2013199","journal-title":"Fibrinolysis"},{"key":"4_CR105","doi-asserted-by":"crossref","first-page":"8619","DOI":"10.1016\/S0021-9258(18)34171-1","volume":"257","author":"CF Reilly","year":"1982","unstructured":"Reilly CF, Tewksbury DA, Schechter NM, Travis J (1982) Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem 257:8619\u20138622","journal-title":"J Biol Chem"},{"key":"4_CR106","doi-asserted-by":"crossref","first-page":"15042","DOI":"10.1016\/S0021-9258(18)33390-8","volume":"257","author":"LB Klickstein","year":"1982","unstructured":"Klickstein LB, Kaempfer CE, Wintroub BU (1982) The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G. J Biol Chem 257:15042\u201315046","journal-title":"J Biol Chem"},{"key":"4_CR107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jcp.10014","volume":"189","author":"P Shamamian","year":"2001","unstructured":"Shamamian P, Schwartz JD, Pocock BJZ et al (2001) Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 189:197\u2013206","journal-title":"J Cell Physiol"},{"key":"4_CR108","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.02.008","volume":"68","author":"P Benes","year":"2008","unstructured":"Benes P, Vetvicka V, Fusek M (2008) Cathepsin D-Many functions of one aspartic protease. Crit Rev Oncol Hematol 68:12\u201328","journal-title":"Crit Rev Oncol Hematol"},{"key":"4_CR109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/CBM-2010-0143","volume":"7","author":"G Nicotra","year":"2010","unstructured":"Nicotra G, Castino R, Follo C et al (2010) The dilemma: Does tissue expression of cathepsin D reflect tumor malignancy? the question: does the assay truly mirror cathepsin D mis-function in the tumor? Cancer Biomarkers 7:47\u201364","journal-title":"Cancer Biomarkers"},{"key":"4_CR110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.canlet.2012.04.012","volume":"323","author":"YS Hah","year":"2012","unstructured":"Hah YS, Noh HS, Ha JH et al (2012) Cathepsin D inhibits oxidative stress-induced cell death via activation of autophagy in cancer cells. Cancer Lett 323:208\u2013214","journal-title":"Cancer Lett"},{"key":"4_CR111","first-page":"901","volume":"32","author":"D Dian","year":"2012","unstructured":"Dian D, Vrekoussis T, Shabani N et al (2012) Expression of cathepsin-D in primary breast cancer and corresponding local recurrence or metastasis: an immunohistochemical study. Anticancer Res 32:901\u2013905","journal-title":"Anticancer Res"},{"key":"4_CR112","first-page":"383","volume":"56","author":"I Lentari","year":"2002","unstructured":"Lentari I, Segas I, Kandiloros D (2002) The importance of cathepsin\u2019s-D tissular detection in laryngeal squamous cell carcinoma. Acta Otorhinolaryngol Belg 56:383\u2013389","journal-title":"Acta Otorhinolaryngol Belg"},{"key":"4_CR113","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00432-011-1007-z","volume":"137","author":"M Paksoy","year":"2011","unstructured":"Paksoy M, Hardal U, Caglar C (2011) Expression of Cathepsin D and E-Cadherin in primary laryngeal cancers correlation with neck lymph node involvement. J Cancer Res Clin Oncol 137:1371\u20131377","journal-title":"J Cancer Res Clin Oncol"},{"key":"4_CR114","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1158\/0008-5472.CAN-11-1367","volume":"71","author":"L Dumartin","year":"2011","unstructured":"Dumartin L, Whiteman HJ, Weeks ME et al (2011) AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res 71:7091\u20137102","journal-title":"Cancer Res"},{"key":"4_CR115","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ygyno.2003.11.016","volume":"92","author":"A L\u00f6sch","year":"2004","unstructured":"L\u00f6sch A, Schindl M, Kohlberger P et al (2004) Cathepsin D in ovarian cancer: prognostic value and correlation with p 53 expression and microvessel density. Gynecol Oncol 92:545\u2013552","journal-title":"Gynecol Oncol"},{"key":"4_CR116","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2559.1999.00548.x","volume":"34","author":"MC Gonz\u00e1lez-Vela","year":"1999","unstructured":"Gonz\u00e1lez-Vela MC, Garijo MF, Fern\u00e1ndez F et al (1999) Cathepsin D in host stromal cells is associated with more highly vascular and aggressive invasive breast carcinoma. Histopathology 34:35\u201342","journal-title":"Histopathology"},{"key":"4_CR117","first-page":"491","volume":"32","author":"SS Ohri","year":"2008","unstructured":"Ohri SS, Vashishta A, Proctor M et al (2008) The propeptide of cathepsin D increases proliferation, invasion and metastasis of breast cancer cells. Int J Oncol 32:491\u2013498","journal-title":"Int J Oncol"},{"key":"4_CR118","first-page":"4163","volume":"26","author":"A Vashishta","year":"2006","unstructured":"Vashishta A, Ohri SS, Proctor M et al (2006) Role of activation peptide of procathepsin D in proliferation and invasion of lung cancer cells. Anticancer Res 26:4163\u20134170","journal-title":"Anticancer Res"},{"key":"4_CR119","first-page":"651","volume":"18","author":"SD Szajda","year":"2005","unstructured":"Szajda SD, Darewicz B, Kudelski J et al (2005) Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer. Pol Merkur Lek 18:651\u2013653","journal-title":"Pol Merkur Lek"},{"key":"4_CR120","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/030089160609200308","volume":"92","author":"C Tokyol","year":"2006","unstructured":"Tokyol C, K\u00f6ken T, Demirbas M et al (2006) Expression of cathepsin D in bladder carcinoma: correlation with pathological features and serum cystatin C levels. Tumori 92:230\u2013235","journal-title":"Tumori"},{"key":"4_CR121","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/sj.onc.1209196","volume":"25","author":"D Jean","year":"2006","unstructured":"Jean D, Rousselet N, Frade R (2006) Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms. Oncogene 25:1474\u20131484","journal-title":"Oncogene"},{"key":"4_CR122","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4331\/wjbc.v4.i4.91","volume":"4","author":"G-J Tan","year":"2013","unstructured":"Tan G-J, Peng Z-K, Lu J-P, Tang F-Q (2013) Cathepsins mediate tumor metastasis. World J Biol Chem 4:91\u2013101","journal-title":"World J Biol Chem"},{"key":"4_CR123","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrm2125","volume":"8","author":"A Page-McCaw","year":"2007","unstructured":"Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8:221\u2013233","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4_CR124","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","volume":"2","author":"M Egeblad","year":"2002","unstructured":"Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161\u2013174","journal-title":"Nat Rev Cancer"},{"key":"4_CR125","first-page":"18","volume":"25","author":"N Sun","year":"2014","unstructured":"Sun N, Zhao Q, Ye C et al (2014) Role of matrix metalloproteinase-1 (MMP-1)\/protease-activated receptor-1 (PAR-1) signaling pathway in the cervical cancer invasion. J Reprod Contracept 25:18\u201325","journal-title":"J Reprod Contracept"},{"key":"4_CR126","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.cellbio.17.1.463","volume":"17","author":"MD Sternlicht","year":"2001","unstructured":"Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463\u2013516","journal-title":"Annu Rev Cell Dev Biol"},{"key":"4_CR127","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52\u201367","journal-title":"Cell"},{"key":"4_CR128","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.clinbiochem.2007.01.021","volume":"40","author":"K Vasala","year":"2007","unstructured":"Vasala K, Turpeenniemi-Hujanen T (2007) Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. Clin Biochem 40:640\u2013644","journal-title":"Clin Biochem"},{"key":"4_CR129","first-page":"577","volume":"61","author":"N Mitsiades","year":"2001","unstructured":"Mitsiades N, Yu WH, Poulaki V et al (2001) Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 61:577\u2013581","journal-title":"Cancer Res"},{"issue":"Suppl","key":"4_CR130","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1007\/s002800051097","volume":"43","author":"DE Kleiner","year":"1999","unstructured":"Kleiner DE, Stetler-Stevenson WG (1999) Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43(Suppl):S42\u2013S51","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1 INHIBITION OF","key":"4_CR131","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1749-6632.1999.tb07680.x","volume":"878","author":"R. HANEMAAIJER","year":"1999","unstructured":"Hanemaaijer R, Sier CFM, Visser H et al (1999) MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate. Ann N Y Acad Sci:141\u2013149","journal-title":"Annals of the New York Academy of Sciences"},{"key":"4_CR132","first-page":"467","volume":"1","author":"IM Margulies","year":"1992","unstructured":"Margulies IM, Hoyhtya M, Evans C et al (1992) Urinary type-IV collagenase\u2014elevated levels are associated with bladder transitional cell-carcinoma. Cancer Epidemiol Biomark Prev 1:467\u2013474","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"4_CR133","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1158\/0008-5472.CAN-07-5046","volume":"68","author":"KD Cowden Dahl","year":"2008","unstructured":"Cowden Dahl KD, Symowicz J, Ning Y et al (2008) Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells. Cancer Res 68:4606\u20134613","journal-title":"Cancer Res"},{"key":"4_CR134","doi-asserted-by":"crossref","first-page":"9182","DOI":"10.1073\/pnas.0500918102","volume":"102","author":"T Maretzky","year":"2005","unstructured":"Maretzky T, Reiss K, Ludwig A et al (2005) ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci U S A 102:9182\u20139187","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4_CR135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massagu\u00e9","year":"2008","unstructured":"Massagu\u00e9 J (2008) TGF beta in Cancer. Cell 134:215\u2013230","journal-title":"Cell"},{"key":"4_CR136","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1101\/gad.14.2.163","volume":"14","author":"Q Yu","year":"2000","unstructured":"Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14:163\u2013176","journal-title":"Genes Dev"},{"key":"4_CR137","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1158\/0008-5472.CAN-07-6768","volume":"68","author":"I Waldhauer","year":"2008","unstructured":"Waldhauer I, Goehlsdorf D, Gieseke F et al (2008) Tumor-associated MICA is shed by ADAM proteases. Cancer Res 68:6368\u20136376","journal-title":"Cancer Res"},{"key":"4_CR138","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/intimm\/dxn038","volume":"20","author":"Chansac B Maux Le","year":"2008","unstructured":"Le Maux Chansac B, Miss\u00e9 D, Richon C et al (2008) Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway. Int Immunol 20:801\u2013810","journal-title":"Int Immunol"},{"key":"4_CR139","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/35036374","volume":"2","author":"G Bergers","year":"2000","unstructured":"Bergers G, Brekken R, McMahon G et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737\u2013744","journal-title":"Nat Cell Biol"},{"key":"4_CR140","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1074\/jbc.275.4.2661","volume":"275","author":"MW Olson","year":"2000","unstructured":"Olson MW, Bernardo MM, Pietila M et al (2000) Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9: differential rates for activation by stromelysin 1. J Biol Chem 275:2661\u20132668","journal-title":"J Biol Chem"},{"key":"4_CR141","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/1471-2407-9-390","volume":"9","author":"X Provatopoulou","year":"2009","unstructured":"Provatopoulou X, Gounaris A, Kalogera E et al (2009) Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9\/NGAL in breast cancer disease. BMC Cancer 9:390","journal-title":"BMC Cancer"},{"key":"4_CR142","doi-asserted-by":"crossref","first-page":"37258","DOI":"10.1074\/jbc.M106089200","volume":"276","author":"L Yan","year":"2001","unstructured":"Yan L, Borregaard N, Kjeldsen L, Moses MA (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B\/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL): Modulation of MMP-9 activity by NGAL. J Biol Chem 276:37258\u201337265","journal-title":"J Biol Chem"},{"key":"4_CR143","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1083\/jcb.147.1.89","volume":"147","author":"JA Aguirre Ghiso","year":"1999","unstructured":"Aguirre Ghiso JA, Kovalski K, Ossowski L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147:89\u2013103","journal-title":"J Cell Biol"},{"key":"4_CR144","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/15216540400013903","volume":"56","author":"S Eissa","year":"2004","unstructured":"Eissa S, Ahmed MI, Said H et al (2004) Cell cycle regulators in bladder cancer: relationship to schistosomiasis. IUBMB Life 56:557\u2013564","journal-title":"IUBMB Life"},{"key":"4_CR145","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/iub.186","volume":"61","author":"E Cera Di","year":"2009","unstructured":"Di Cera E (2009) Serine Proteases. IUBMB Life 61:510\u2013515. doi: 10.1002\/iub.186","journal-title":"IUBMB Life"},{"key":"4_CR146","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.brainres.2011.06.042","volume":"1407","author":"AG Almonte","year":"2011","unstructured":"Almonte AG, Sweatt JD (2011) Serine proteases, serine protease inhibitors, and protease-activated receptors: roles in synaptic function and behavior. Brain Res 1407:107\u2013122","journal-title":"Brain Res"},{"key":"4_CR147","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1086\/431600","volume":"192","author":"T Jin","year":"2005","unstructured":"Jin T, Bokarewa M, Tarkowski A (2005) Urokinase-type plasminogen activator, an endogenous antibiotic. J Infect Dis 192:429\u2013437. doi: 10.1086\/431600","journal-title":"J Infect Dis"},{"key":"4_CR148","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0022-2143(99)90084-7","volume":"133","author":"MR Gyetko","year":"1999","unstructured":"Gyetko MR, Libre EA, Fuller JA et al (1999) Urokinase is required for T lymphocyte proliferation and activation in vitro. J Lab Clin Med 133:274\u2013288","journal-title":"J Lab Clin Med"},{"key":"4_CR149","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1083\/jcb.100.1.86","volume":"100","author":"JD Vassalli","year":"1985","unstructured":"Vassalli JD (1985) A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100:86\u201392","journal-title":"J Cell Biol"},{"key":"4_CR150","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2012.02569.x","volume":"272","author":"R Uusitalo-Sepp\u00e4l\u00e4","year":"2012","unstructured":"Uusitalo-Sepp\u00e4l\u00e4 R, Huttunen R, Tarkka M et al (2012) Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J Intern Med 272:247\u2013256","journal-title":"J Intern Med"},{"key":"4_CR151","first-page":"109","volume":"17","author":"J Jankun","year":"1999","unstructured":"Jankun J, Skrzypczak-Jankun E (1999) Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. Cancer Biochem Biophys 17:109\u2013123","journal-title":"Cancer Biochem Biophys"},{"key":"4_CR152","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1381612043453559","volume":"10","author":"MJ Duffy","year":"2004","unstructured":"Duffy MJ (2004) The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10:39\u201349","journal-title":"Curr Pharm Des"},{"issue":"19","key":"4_CR153","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2174\/1381612033454612","volume":"9","author":"Ute Reuning","year":"2003","unstructured":"Reuning U, Sperl S, Kopitz C et al Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA\/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des 9:1529\u20131543","journal-title":"Current Pharmaceutical Design"},{"key":"4_CR154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z","volume":"72","author":"PA Andreasen","year":"1997","unstructured":"Andreasen PA, Kj\u00f8ller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1\u201322","journal-title":"Int J Cancer"},{"key":"4_CR155","first-page":"4887","volume":"56","author":"S Gately","year":"1996","unstructured":"Gately S, Twardowski P, Stack MS et al (1996) Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 56:4887\u20134890","journal-title":"Cancer Res"},{"key":"4_CR156","doi-asserted-by":"crossref","first-page":"14151","DOI":"10.1016\/S0021-9258(19)49691-9","volume":"267","author":"S Rabbani","year":"1992","unstructured":"Rabbani S, Mazar A, Bernier S et al (1992) Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 267:14151\u201314156","journal-title":"J Biol Chem"},{"key":"4_CR157","doi-asserted-by":"crossref","first-page":"16450","DOI":"10.1074\/jbc.M909080199","volume":"275","author":"S Mukhina","year":"2000","unstructured":"Mukhina S, Stepanova V, Traktouev D et al (2000) The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis. J Biol Chem 275:16450\u201316458","journal-title":"J Biol Chem"},{"key":"4_CR158","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ijc.2910500607","volume":"50","author":"Y Hasui","year":"1992","unstructured":"Hasui Y, Marutsuka K, Suzumiya J et al (1992) The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 50:871\u2013873","journal-title":"Int J Cancer"},{"key":"4_CR159","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-60327-003-8_9","volume":"539","author":"JO McIntyre","year":"2009","unstructured":"McIntyre JO, Matrisian LM (2009) Optical proteolytic beacons for in vivo detection of matrix metalloproteinase activity. Methods Mol Biol 539:155\u2013174","journal-title":"Methods Mol Biol"},{"key":"4_CR160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.matbio.2008.10.001","volume":"28","author":"BZ Packard","year":"2009","unstructured":"Packard BZ, Artym VV, Komoriya A, Yamada KM (2009) Direct visualization of protease activity on cells migrating in three-dimensions. Matrix Biol 28:3\u201310","journal-title":"Matrix Biol"},{"key":"4_CR161","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/89126","volume":"7","author":"C Bremer","year":"2001","unstructured":"Bremer C, Tung CH, Weissleder R (2001) In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 7:743\u2013748","journal-title":"Nat Med"},{"key":"4_CR162","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1248\/bpb.32.1272","volume":"32","author":"T Temma","year":"2009","unstructured":"Temma T, Sano K, Kuge Y et al (2009) Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors. Biol Pharm Bull 32:1272\u20131277","journal-title":"Biol Pharm Bull"},{"key":"4_CR163","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0969-8051(02)00393-1","volume":"30","author":"S Furumoto","year":"2003","unstructured":"Furumoto S, Takashima K, Kubota K et al (2003) Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol 30:119\u2013125","journal-title":"Nucl Med Biol"},{"key":"4_CR164","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.urolonc.2008.04.012","volume":"27","author":"SC Smith","year":"2009","unstructured":"Smith SC, Theodorescu D (2009) The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target. Urol Oncol Semin Orig Investig 27:42\u201347","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"4_CR165","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1097\/01.ju.0000088670.02905.78","volume":"170","author":"G Oxford","year":"2003","unstructured":"Oxford G, Theodorescu D (2003) The role of Ras superfamily proteins in bladder cancer progression. J Urol 170:1987\u20131993","journal-title":"J Urol"},{"key":"4_CR166","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.mrrev.2013.01.002","volume":"753","author":"AK Chaudhary","year":"2013","unstructured":"Chaudhary AK, Pandya S, Ghosh K, Nadkarni A (2013) Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview. Mutat Res\u2014Rev Mutat Res 753:7\u201323","journal-title":"Mutat Res\u2014Rev Mutat Res"},{"key":"4_CR167","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/bjc.2013.420","volume":"109","author":"M Santoni","year":"2013","unstructured":"Santoni M, Amantini C, Morelli MB et al (2013) Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer 109:1040\u20131050","journal-title":"Br J Cancer"},{"key":"4_CR168","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00280-014-2496-7","volume":"74","author":"H Ishiguro","year":"2014","unstructured":"Ishiguro H, Kawahara T, Zheng Y et al (2014) Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity. Cancer Chemother Pharmacol 74:249\u2013255","journal-title":"Cancer Chemother Pharmacol"},{"key":"4_CR169","doi-asserted-by":"crossref","unstructured":"Cheng DLW, Shu WP, Choi JCS et al (1994) Bacillus Calmette-Guerin interacts with the carboxyl-terminal heparin binding domain of fibronectin: implications for BCG-mediated antitumor activity. J Urol 152:1275\u20131280","DOI":"10.1016\/S0022-5347(17)32567-3"},{"key":"4_CR170","first-page":"5224","volume":"63","author":"D Belotti","year":"2003","unstructured":"Belotti D, Paganoni P, Manenti L et al (2003) Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 63:5224\u20135229","journal-title":"Cancer Res"},{"key":"4_CR171","first-page":"823","volume":"20","author":"E Sandes","year":"2007","unstructured":"Sandes E, Lodillinsky C, Cwirenbaum R et al (2007) Cathepsin B is involved in the apoptosis intrinsic pathway induced by Bacillus Calmette-Guerin in transitional cancer cell lines. Int J Mol Med 20:823\u2013828","journal-title":"Int J Mol Med"},{"key":"4_CR172","doi-asserted-by":"crossref","first-page":"e1091146","DOI":"10.1080\/2162402X.2015.1091146","volume":"5","author":"C Dezutter-Dambuyant","year":"2016","unstructured":"Dezutter-Dambuyant C, Durand I, Alberti L et al (2016) A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. Oncoimmunology 5:e1091146","journal-title":"Oncoimmunology"}],"container-title":["Pathophysiological Aspects of Proteases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-10-6141-7_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T18:52:31Z","timestamp":1719600751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-981-10-6141-7_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9789811061400","9789811061417"],"references-count":172,"URL":"https:\/\/doi.org\/10.1007\/978-981-10-6141-7_4","relation":{},"subject":[],"published":{"date-parts":[[2017]]}}}